Association Between Pioglitazone Use and Prostate Cancer: A Population-Based Case-Control Study in the Han Population

Li Ting Kao, Sudha Xirasagar, Herng Ching Lin, Chao Yuan Huang

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

To date, few epidemiologic studies have investigated the relationship between pioglitazone use and prostate cancer. The available studies show conflicting findings. This case-control study explored the association between prior pioglitazone usage and prostate cancer using a large, population-based data set. Data were derived from the Longitudinal Health Insurance Database 2005 in Taiwan, a population-based sample of National Health Insurance enrollees with longitudinal claims data since 1995. Cases were 3513 patients with prostate cancer aged over 40 years, and the controls were 3513 patients without prostate cancer, matched with prostate cancer cases on age, and having a medical care utilization episode in the year of the index prostate cancer (1 control per case). We performed conditional logistic regression to examine the odds ratio and 95% confidence intervals for prior pioglitazone use between cases and controls. Analysis showed that 178 of the total sample patients (2.53%) had used pioglitazone prior to the index date. Prior pioglitazone use was found in 72 (2.05%) cases and 106 (3.02%) controls. The crude odds ratio of prior pioglitazone usage for cases was 0.67 (95% confidence interval, 0.50-0.91) compared to controls. After adjusting for demographic characteristics and comorbidities, the negative association of prior pioglitazone with prostate cancer persisted (adjusted odds ratio, 0.59; 95% confidence interval, 0.43-0.80). We concluded that there was an inverse association between prior pioglitazone usage and prostate cancer in this study.

Original languageEnglish
JournalJournal of Clinical Pharmacology
DOIs
Publication statusAccepted/In press - Jan 1 2018

Fingerprint

pioglitazone
Case-Control Studies
Prostatic Neoplasms
Population
Odds Ratio
Confidence Intervals
Episode of Care
National Health Programs
Health Insurance
Taiwan

Keywords

  • pioglitazone
  • prostate cancer
  • thiazolidinedione

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Association Between Pioglitazone Use and Prostate Cancer : A Population-Based Case-Control Study in the Han Population. / Kao, Li Ting; Xirasagar, Sudha; Lin, Herng Ching; Huang, Chao Yuan.

In: Journal of Clinical Pharmacology, 01.01.2018.

Research output: Contribution to journalArticle

@article{ce1eda230c764e36a946ef331010921a,
title = "Association Between Pioglitazone Use and Prostate Cancer: A Population-Based Case-Control Study in the Han Population",
abstract = "To date, few epidemiologic studies have investigated the relationship between pioglitazone use and prostate cancer. The available studies show conflicting findings. This case-control study explored the association between prior pioglitazone usage and prostate cancer using a large, population-based data set. Data were derived from the Longitudinal Health Insurance Database 2005 in Taiwan, a population-based sample of National Health Insurance enrollees with longitudinal claims data since 1995. Cases were 3513 patients with prostate cancer aged over 40 years, and the controls were 3513 patients without prostate cancer, matched with prostate cancer cases on age, and having a medical care utilization episode in the year of the index prostate cancer (1 control per case). We performed conditional logistic regression to examine the odds ratio and 95{\%} confidence intervals for prior pioglitazone use between cases and controls. Analysis showed that 178 of the total sample patients (2.53{\%}) had used pioglitazone prior to the index date. Prior pioglitazone use was found in 72 (2.05{\%}) cases and 106 (3.02{\%}) controls. The crude odds ratio of prior pioglitazone usage for cases was 0.67 (95{\%} confidence interval, 0.50-0.91) compared to controls. After adjusting for demographic characteristics and comorbidities, the negative association of prior pioglitazone with prostate cancer persisted (adjusted odds ratio, 0.59; 95{\%} confidence interval, 0.43-0.80). We concluded that there was an inverse association between prior pioglitazone usage and prostate cancer in this study.",
keywords = "pioglitazone, prostate cancer, thiazolidinedione",
author = "Kao, {Li Ting} and Sudha Xirasagar and Lin, {Herng Ching} and Huang, {Chao Yuan}",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/jcph.1326",
language = "English",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",

}

TY - JOUR

T1 - Association Between Pioglitazone Use and Prostate Cancer

T2 - A Population-Based Case-Control Study in the Han Population

AU - Kao, Li Ting

AU - Xirasagar, Sudha

AU - Lin, Herng Ching

AU - Huang, Chao Yuan

PY - 2018/1/1

Y1 - 2018/1/1

N2 - To date, few epidemiologic studies have investigated the relationship between pioglitazone use and prostate cancer. The available studies show conflicting findings. This case-control study explored the association between prior pioglitazone usage and prostate cancer using a large, population-based data set. Data were derived from the Longitudinal Health Insurance Database 2005 in Taiwan, a population-based sample of National Health Insurance enrollees with longitudinal claims data since 1995. Cases were 3513 patients with prostate cancer aged over 40 years, and the controls were 3513 patients without prostate cancer, matched with prostate cancer cases on age, and having a medical care utilization episode in the year of the index prostate cancer (1 control per case). We performed conditional logistic regression to examine the odds ratio and 95% confidence intervals for prior pioglitazone use between cases and controls. Analysis showed that 178 of the total sample patients (2.53%) had used pioglitazone prior to the index date. Prior pioglitazone use was found in 72 (2.05%) cases and 106 (3.02%) controls. The crude odds ratio of prior pioglitazone usage for cases was 0.67 (95% confidence interval, 0.50-0.91) compared to controls. After adjusting for demographic characteristics and comorbidities, the negative association of prior pioglitazone with prostate cancer persisted (adjusted odds ratio, 0.59; 95% confidence interval, 0.43-0.80). We concluded that there was an inverse association between prior pioglitazone usage and prostate cancer in this study.

AB - To date, few epidemiologic studies have investigated the relationship between pioglitazone use and prostate cancer. The available studies show conflicting findings. This case-control study explored the association between prior pioglitazone usage and prostate cancer using a large, population-based data set. Data were derived from the Longitudinal Health Insurance Database 2005 in Taiwan, a population-based sample of National Health Insurance enrollees with longitudinal claims data since 1995. Cases were 3513 patients with prostate cancer aged over 40 years, and the controls were 3513 patients without prostate cancer, matched with prostate cancer cases on age, and having a medical care utilization episode in the year of the index prostate cancer (1 control per case). We performed conditional logistic regression to examine the odds ratio and 95% confidence intervals for prior pioglitazone use between cases and controls. Analysis showed that 178 of the total sample patients (2.53%) had used pioglitazone prior to the index date. Prior pioglitazone use was found in 72 (2.05%) cases and 106 (3.02%) controls. The crude odds ratio of prior pioglitazone usage for cases was 0.67 (95% confidence interval, 0.50-0.91) compared to controls. After adjusting for demographic characteristics and comorbidities, the negative association of prior pioglitazone with prostate cancer persisted (adjusted odds ratio, 0.59; 95% confidence interval, 0.43-0.80). We concluded that there was an inverse association between prior pioglitazone usage and prostate cancer in this study.

KW - pioglitazone

KW - prostate cancer

KW - thiazolidinedione

UR - http://www.scopus.com/inward/record.url?scp=85055159405&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055159405&partnerID=8YFLogxK

U2 - 10.1002/jcph.1326

DO - 10.1002/jcph.1326

M3 - Article

AN - SCOPUS:85055159405

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

ER -